20 March 2013 3.8 million Euro grant to support CVac Development; Prima moving forward with pilot of CVac in additional cancer indications >>

[at noodls] – 3.8 million Euro grant to support CVac Development; Prima moving forward with pilot of CVac in additional cancer indications Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) (Prima, … more

View todays social media effects on PBMD

View the latest stocks trending across Twitter. Click to view dashboard

See who Prima is hiring next, click here to view